Perspective Therapeutics (NYSEAMERICAN:CATX) Announces Quarterly Earnings Results

Perspective Therapeutics (NYSEAMERICAN:CATX) posted its quarterly earnings results on Monday. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.05, FiscalAI reports. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.09 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%.

Perspective Therapeutics Price Performance

NYSEAMERICAN:CATX remained flat at $3.00 during trading hours on Monday. The company had a trading volume of 911,985 shares, compared to its average volume of 2,355,088. Perspective Therapeutics has a 52-week low of $1.96 and a 52-week high of $6.16. The company has a 50-day simple moving average of $3.11 and a two-hundred day simple moving average of $3.93.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CATX. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth about $28,000. Russell Investments Group Ltd. boosted its holdings in Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after purchasing an additional 5,475 shares in the last quarter. nVerses Capital LLC purchased a new position in Perspective Therapeutics in the fourth quarter valued at approximately $31,000. Engineers Gate Manager LP purchased a new position in Perspective Therapeutics in the fourth quarter valued at approximately $35,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Perspective Therapeutics during the fourth quarter worth approximately $42,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Analyst Ratings Changes

CATX has been the topic of a number of recent research reports. Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, May 5th. BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Eight investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $12.62.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.